Medinol Ltd
Medinol, Ariad Pharmaceuticals launch stent trials
Medinol goes after J&J’s Cordis in stent patent war
Cordis Corp., the stent-making arm of Johnson & Johnson (NYSE:JNJ), got out of the coronary stent game 2 years ago, but that’s not stopping Israeli medical device company Medinol from suing Cordis for patent infringement with the Cypher and Cypher Select stents it no longer makes.
FDA clears Ethicon’s 1st surgical set docs can assemble inside the body | Regulatory Roundup
Johnson & Johnson (NYSE:JNJ) Ethicon Endo-Surgery won FDA clearance for the 1st surgical instruments that can be assembled and disassembled inside the body during surgery.
Stents: Medtronic’s subclavian approach for valve-replacement device achieved “excellent” results in clinical trial | PCR 2011 Roundup
Boston Scientific wins back $104 million from Medinol
Boston Scientific Corp. (NYSE:BSX) added $104 million to its 2010 top line in the last week of the year.
The Natick, Mass.-based medical device giant reached a new agreement with Medinol Ltd. on a dispute over 2001 litigation regarding intellectual property theft and contractual obligations involving the companies’ coronary stents.
OrbusNeich touts Dutch court decision against patent foe Boston Scientific
OrbusNeich Medical Inc. hailed the decision of a Dutch court in its ongoing stent patent spat with Boston Scientific Corp. (NYSE:BSX).
The District Court of The Hague, Netherlands ruled that Boston Scientific’s lawsuit accusing Orbus of infringing a Boston Scientific patent with its Evolution 2 catheter could not proceed, according to Orbus.